(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 July 2012 (19.07.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/095469 A1

(51) International Patent Classification:
*C07D 413/14* (2006.01) *A61K 31/5377* (2006.01)
*C07D 487/04* (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:
PCT/EP2012/050395

(22) International Filing Date:
11 January 2012 (11.01.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
77/DEL/2011 13 January 2011 (13.01.2011) IN
61/534,591 14 September 2011 (14.09.2011) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BADIGER, Sangamesh** [IN/IN]; Aurigene Discovery Technologies Limited, 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road, Bangalore, Karnataka 560 100 (IN). **CHEBROLU, Murali** [IN/IN]; Aurigene Discovery Technologies Limited, 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road, Bangalore, Karnataka 560 100 (IN). **HURTH, Konstanze** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **JACQUIER, Sébastien** [FR/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **LUEOEND, Rainer Martin** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **MACHAUER, Rainer** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **RUEEGER, Heinrich** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **TINTELNOT-BLOMLEY, Marina** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **VEENSTRA, Siem Jacob** [NL/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **VOEGTLE, Markus** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH).

(74) Agent: **CAMPBELL, Lachlan**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Declarations under Rule 4.17**:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published**:

— *with international search report (Art. 21(3))*

(54) Title: NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS




(I)

(57) Abstract: The invention relates to novel heterocyclic compounds of the Formula (I), in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

WO 2012/095469 A1